Lanzhou Foci Pharmaceutical Co Ltd

Lanzhou Foci Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 3.02, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity FPT (free cash flow to total liabilities) is not explicitly provided, but the free cash flow of 75.87 million CNY supports its ability to service liabilities. However, the company has a net cash position that is negative after subtracting total debt, which introduces a medium liquidity risk. In terms of profitability, the company's return on equity (ROE) is 2.68%, and its return on assets (ROA) is 1.93%. These figures are relatively low compared to industry benchmarks, suggesting that the company is not generating strong returns relative to its equity and asset base. The price-to-earnings (P/E) ratio of 80.53 is significantly higher than the industry median, indicating that the stock is trading at a premium relative to its earnings. The company's revenue is primarily concentrated in its domestic operations, with no significant international exposure disclosed. The lack of geographic diversification may increase its vulnerability to local economic and regulatory changes. The company operates in a single business segment, which is typical for many pharmaceutical firms in China, but it also means that its performance is closely tied to the success of its core product lines. Looking at the growth trajectory, the company's revenue for the latest period was 915.53 million CNY, and the net income was 49.21 million CNY. While the company has a positive net income, the growth rate is not explicitly provided. The capital expenditure of -18.55 million CNY suggests that the company is not investing heavily in new projects or infrastructure, which could limit its long-term growth potential. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.05, which is relatively low, suggesting that it is not heavily leveraged. However, the negative net cash position after subtracting total debt is a concern and could affect its ability to fund operations or investments without external financing. Recent events and filings do not show any significant changes in the company's operations or financial structure. The latest analyst estimates indicate that the company's last actual EPS was 0.15 CNY, and the last actual revenue was 544.58 million CNY. These figures are lower than the company's reported financials, which may indicate a discrepancy or a change in reporting periods.